Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

Multidrug resistance is often associated with the (over)expression of drug efflux transporters of the ATP-binding cassette (ABC) protein family. This minireview discusses the role of one selected ABC-transporter family member, the breast cancer resistance protein (BCRP/ABCG2), in the (pre)clinical efficacy of novel experimental anticancer drugs, in particular tyrosine kinase inhibitors.

[1]  D. Ross,et al.  Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. , 2006, Blood.

[2]  Y. Wang,et al.  Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells , 2007, Leukemia.

[3]  M. Gottesman,et al.  The molecular basis of multidrug resistance in cancer: The early years of P‐glycoprotein research , 2006, FEBS letters.

[4]  Y. Sugimoto,et al.  Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. , 2006, Cancer letters.

[5]  H. Berenbaum,et al.  Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. , 2006, Blood.

[6]  Daxi Sun,et al.  Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. , 2007, Cancer research.

[7]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[8]  Mariël Brok,et al.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.

[9]  T. Utsunomiya,et al.  Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System , 2006, Stem cells.

[10]  G. Szakács,et al.  Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.

[11]  T. Dale,et al.  Contribution of the ABC Transporters Bcrp1 and Mdr1a/1b to the Side Population Phenotype in Mammary Gland and Bone Marrow of Mice , 2005, Stem cells.

[12]  P. Houghton,et al.  Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.

[13]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[14]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[15]  I. Shiojima,et al.  Akt Signaling Regulates Side Population Cell Phenotype via Bcrp1 Translocation* , 2003, Journal of Biological Chemistry.

[16]  S. Bates,et al.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.

[17]  S H Kaufmann,et al.  The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.

[18]  J. Schellens,et al.  The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. , 2005, Cancer research.

[19]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[20]  Mariël Brok,et al.  Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump , 2004 .

[21]  G. Kéri,et al.  Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.

[22]  Mariël Brok,et al.  Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.

[23]  R. Pieters,et al.  Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment , 2006, Cancer Chemotherapy and Pharmacology.

[24]  Y. Sugimoto,et al.  Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.

[25]  S. Bates,et al.  Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib , 2006, Clinical pharmacology and therapeutics.

[26]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Yehuda G Assaraf,et al.  Cytoplasmic Confinement of Breast Cancer Resistance Protein (BCRP/ABCG2) as a Novel Mechanism of Adaptation to Short-Term Folate Deprivation , 2005, Molecular Pharmacology.

[28]  G. Kéri,et al.  Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. , 2002, Biochimica et biophysica acta.

[29]  G. Camenisch,et al.  Modulation of the Brain Distribution of Imatinib and its Metabolites in Mice by Valspodar, Zosuquidar and Elacridar , 2007, Pharmaceutical Research.

[30]  S. Bates,et al.  ABCG2: determining its relevance in clinical drug resistance , 2007, Cancer and Metastasis Reviews.

[31]  S. Kohno,et al.  Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. , 2005, Cancer research.

[32]  Z. Sauna,et al.  Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2 , 2008, Leukemia.

[33]  Y. Assaraf.  The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[34]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.

[35]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[36]  M. Hidalgo,et al.  Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. , 2006, Journal of the National Cancer Institute.